# T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?

Source: [nature.com](https://www.nature.com/articles/s41571-026-01230-2) · 2026-11-10 · Medicine
Page: https://themorning.science/story/t-cell-redirection-in-high-risk-smouldering-multiple-myeloma-can-deep-responses-f4494b225f44bee2
Kind: research · Impact: medium

## In brief

- A randomized phase II trial called ImmunoPRISM tested teclistamab in high-risk smouldering multiple myeloma.
- The trial showed encouraging efficacy for the BCMA-targeted bispecific T cell engager teclistamab.
- The source reports the study in Nature Reviews Clinical Oncology, published online 10 November 2026.

## Why it matters

It offers early evidence that T cell redirection therapy may produce deep responses in a precursor stage of myeloma, which could inform whether treatment should start before symptomatic disease develops.

## Timeline

- 2026-11-10: Results of the ImmunoPRISM trial published online in Nature Reviews Clinical Oncology

## Coverage

- [T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?](https://www.nature.com/articles/s41571-026-01230-2) — nature.com, 2026-11-10

Tags: multiple myeloma, t cell engager, teclistamab, smouldering myeloma, immunotherapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science